CLASS III Drug recall · Reported 25 Jan 2023 · FDA Enforcement Report

Levofloxacin Tablets, USP 500 mg recalled by Macleods Pharma Usa

Macleods Pharma Usa is recalling Levofloxacin Tablets, USP 500 mg, distributed nationwide in the US. The recall was initiated on 5 Jan 2023 and the FDA has classified it as Class III.

Check your package

Lot, batch or date codesLot #: BLF2214A; Exp. 06/2025
Quantity recalled10052 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0162-2023
FDA event ID
91441
Recalling firm
Macleods Pharma Usa, Princeton, NJ
Classification
Class III
Status
Terminated
Recall initiated
5 Jan 2023
FDA classified
17 Jan 2023
Reported
25 Jan 2023
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Packaging Defects
Drug class
Antibiotics

Timeline

5 Jan 2023Recall initiated by company
17 Jan 2023Classified by FDA+12 days
25 Jan 2023Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Mismatching of the embossing on the tablets (T7) with the embossing mentioned in the package insert (ML63) in the distributed bottles.

Packaging recalls include wrong labels, wrong products in the wrong bottle, missing leaflets, short-filled or empty capsules and seals that fail.

Product as listed by the FDA

Levofloxacin Tablets, USP 500 mg; 50-count bottles, Rx Only, Manufactured for: Macleods Pharma USA, Inc. Princeton, NJ 08540; Manufactured by: Macleods Pharmaceuticals Ltd., Baddi, Himachal Pradesh, India. NDC 33342-022-08

Where it was distributed

Nationwide within United States and Puerto Rico.

Nationwide Puerto Rico

Questions about this recall

Is Levofloxacin Tablets, USP 500 mg recalled?

Yes. Macleods Pharma Usa recalled Levofloxacin Tablets, USP 500 mg on 5 Jan 2023. The recall is Class III and its status is Terminated. Recall number D-0162-2023.

Why was it recalled?

Mismatching of the embossing on the tablets (T7) with the embossing mentioned in the package insert (ML63) in the distributed bottles.

Which lots are affected?

Lot #: BLF2214A; Exp. 06/2025

Where was it sold?

Nationwide within United States and Puerto Rico.

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class III mean?

Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Macleods Pharma Usa

All 34
ReportedClassRecallCompanyReasonWhere
DrugCLASS IILevothyroxine Sodium Tablets USP 150 mcg recalled by Macleods Pharma UsaLevothyroxine SodiumMacleods Pharma UsaPotency & AssayNationwide
DrugCLASS IILosartan Potassium and Hydrochlorothiazide Tablets recalledLosartan Potassium And HydrochlorothiazideMacleods Pharma UsaForeign MaterialNationwide
DrugCLASS IIEszopiclone Tablets, USP 1 mg recalled by Macleods Pharma UsaEszopicloneMacleods Pharma UsaPackaging DefectsNationwide
DrugCLASS IILosartan potassium & Hydrochlorothiazide Tablets 100 mg/25 recalledLosartan Potassium And HydrochlorothiazideMacleods Pharma UsaPotency & AssayNationwide
DrugCLASS IILosartan Potassium & Hydrochlorothiazide Tablets recalledLosartan Potassium And HydrochlorothiazideMacleods Pharma UsaPotency & AssayNationwide

Other Levofloxacin recalls

All 11